Improving Patient Involvement in Medicines Research and Development:: A Practical Roadmap
- PMID: 30231692
- DOI: 10.1177/2168479017706405
Improving Patient Involvement in Medicines Research and Development:: A Practical Roadmap
Abstract
The value of patient involvement (PI) in medicines research and development (R&D) is increasingly recognized by all health stakeholders. Despite numerous ongoing PI initiatives, PI so far lacks structure and consistency in approach. Limited formal documentation of PI activities further hampers the sharing of experience and learnings, preventing timely and systematic implementation. This article summarizes the outcomes of several multistakeholder discussions during 2013-2016 in a practical roadmap for PI in medicines R&D. The roadmap highlights specific opportunities for PI along the 4 key stages of the medicines R&D life cycle and is illustrated with concrete examples. This roadmap's aim is to provide a tool to facilitate PI during medicines research and development and is being shared to encourage implementation and further refinement.
Keywords: patient input; patient involvement roadmap.
Similar articles
-
How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?Int J Evid Based Healthc. 2008 Mar;6(1):78-110. doi: 10.1111/j.1744-1609.2007.00098.x. Int J Evid Based Healthc. 2008. PMID: 21631815
-
A Paradigm Shift Towards Patient Involvement in Medicines Development and Regulatory Science: Workshop Proceedings and Commentary.Ther Innov Regul Sci. 2016 May;50(3):304-311. doi: 10.1177/2168479015622668. Ther Innov Regul Sci. 2016. PMID: 30227074
-
A research roadmap for complementary and alternative medicine - what we need to know by 2020.Forsch Komplementmed. 2014;21(2):e1-16. doi: 10.1159/000360744. Epub 2014 Mar 24. Forsch Komplementmed. 2014. PMID: 24851850
-
Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.Health Technol Assess. 2010 May;14(25):iii-iv, ix-xii, 1-107. doi: 10.3310/hta14250. Health Technol Assess. 2010. PMID: 20501062 Review.
-
Under the Cartagena Protocol on Biosafety - Where is the Roadmap for Risk Assessment Taking Us?Front Bioeng Biotechnol. 2016 Jan 21;3:212. doi: 10.3389/fbioe.2015.00212. eCollection 2015. Front Bioeng Biotechnol. 2016. PMID: 26835448 Free PMC article. Review.
Cited by
-
From Testers to Cocreators-the Value of and Approaches to Successful Patient Engagement in the Development of eHealth Solutions: Qualitative Expert Interview Study.JMIR Hum Factors. 2022 Oct 6;9(4):e41481. doi: 10.2196/41481. JMIR Hum Factors. 2022. PMID: 36102548 Free PMC article.
-
Co-creation of the Global Patient Experience Data Navigator: a multi-stakeholder initiative to ensure the patient voice is represented in health decision-making.Res Involv Engagem. 2023 Oct 12;9(1):92. doi: 10.1186/s40900-023-00503-9. Res Involv Engagem. 2023. PMID: 37828617 Free PMC article.
-
What do stakeholders expect from patient engagement: Are these expectations being met?Health Expect. 2018 Dec;21(6):1035-1045. doi: 10.1111/hex.12797. Epub 2018 Jun 1. Health Expect. 2018. PMID: 29858529 Free PMC article.
-
Patient Preference Studies During Early Drug Development: Aligning Stakeholders to Ensure Development Plans Meet Patient Needs.Front Med (Lausanne). 2019 Apr 24;6:82. doi: 10.3389/fmed.2019.00082. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31069227 Free PMC article.
-
The Launch of the European Patients' Academy on Therapeutic Innovation in the Netherlands: A Qualitative Multi-Stakeholder Analysis.Front Med (Lausanne). 2020 Sep 11;7:558. doi: 10.3389/fmed.2020.00558. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33072776 Free PMC article.
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
